California State Teachers Retirement System Sells 5,000 Shares of Five Prime Therapeutics, Inc. (FPRX)

California State Teachers Retirement System trimmed its holdings in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 9.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,175 shares of the biotechnology company’s stock after selling 5,000 shares during the period. California State Teachers Retirement System owned about 0.17% of Five Prime Therapeutics worth $1,451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. State Street Corp boosted its holdings in shares of Five Prime Therapeutics by 8.4% in the 2nd quarter. State Street Corp now owns 1,354,597 shares of the biotechnology company’s stock valued at $40,782,000 after buying an additional 105,077 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Five Prime Therapeutics by 11.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 933,410 shares of the biotechnology company’s stock valued at $33,743,000 after buying an additional 92,338 shares in the last quarter. BB Biotech AG boosted its stake in Five Prime Therapeutics by 6.9% in the 2nd quarter. BB Biotech AG now owns 777,500 shares of the biotechnology company’s stock worth $23,411,000 after purchasing an additional 50,000 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Five Prime Therapeutics by 28.9% in the 2nd quarter. Victory Capital Management Inc. now owns 666,440 shares of the biotechnology company’s stock worth $20,066,000 after purchasing an additional 149,340 shares in the last quarter. Finally, Marshall Wace North America L.P. boosted its stake in Five Prime Therapeutics by 19.6% in the 2nd quarter. Marshall Wace North America L.P. now owns 341,387 shares of the biotechnology company’s stock worth $10,241,000 after purchasing an additional 56,058 shares in the last quarter. Institutional investors own 81.90% of the company’s stock.

In other news, Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $40.26, for a total transaction of $72,468.00. Following the completion of the transaction, the director now directly owns 1,200 shares of the company’s stock, valued at approximately $48,312. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director William R. Ringo sold 600 shares of Five Prime Therapeutics stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $45.33, for a total transaction of $27,198.00. Following the transaction, the director now directly owns 600 shares of the company’s stock, valued at $27,198. The disclosure for this sale can be found here. Insiders have sold a total of 4,400 shares of company stock valued at $175,666 over the last three months. 6.50% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “California State Teachers Retirement System Sells 5,000 Shares of Five Prime Therapeutics, Inc. (FPRX)” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://sportsperspectives.com/2017/11/21/california-state-teachers-retirement-system-sells-5000-shares-of-five-prime-therapeutics-inc-fprx.html.

Five Prime Therapeutics, Inc. (FPRX) opened at $26.32 on Tuesday. Five Prime Therapeutics, Inc. has a 1 year low of $21.41 and a 1 year high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.19). Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The business had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. During the same period in the prior year, the business posted ($0.72) earnings per share. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. research analysts predict that Five Prime Therapeutics, Inc. will post -5.56 earnings per share for the current year.

FPRX has been the subject of a number of recent analyst reports. Jefferies Group LLC reiterated a “buy” rating and issued a $52.00 target price (down from $55.00) on shares of Five Prime Therapeutics in a research note on Thursday, August 10th. Royal Bank Of Canada reiterated a “buy” rating and issued a $41.00 target price on shares of Five Prime Therapeutics in a research note on Wednesday, October 25th. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 target price for the company in a research note on Monday, October 16th. BMO Capital Markets reiterated a “hold” rating and issued a $39.00 target price on shares of Five Prime Therapeutics in a research note on Friday, September 22nd. Finally, ValuEngine cut shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $64.00.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply